Nuveen
WVE icon

Nuveen’s Wave Life Sciences WVE Stock Holding History

Nuveen’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.19M Sell
549,282
-108,438
-16% -$719K ﹤0.01% 2339
2026
Q1 		$4.77M Buy
657,720
+324,985
+98% +$4.23M ﹤0.01% 1909
2025
Q4 		$5.66M Buy
332,735
+83,266
+33% +$846K ﹤0.01% 1853
2025
Q3 		$1.83M Hold
249,469
– – ﹤0.01% 2340
2025
Q2 		$1.62M Buy
249,469
+199,266
+397% +$1.32M ﹤0.01% 2400
2025
Q1 		$431K Sell
50,203
-503,236
-91% -$5.5M ﹤0.01% 2955
2024
Q4 		$6.85M Buy
553,439
+137,159
+33% +$1.83M ﹤0.01% 1822
2024
Q3 		$3.41M Buy
416,280
+89,390
+27% +$534K ﹤0.01% 2168
2024
Q2 		$1.63M Buy
326,890
+103,540
+46% +$591K ﹤0.01% 2479
2024
Q1 		$1.38M Buy
223,350
+15,579
+7% +$78K ﹤0.01% 2562
2023
Q4 		$1.05M Sell
207,771
-5,067
-2% -$27.1K ﹤0.01% 2710
2023
Q3 		$1.22M Buy
212,838
+6,579
+3% +$30K ﹤0.01% 2491
2023
Q2 		$751K Buy
+206,259
New +$833K ﹤0.01% 2783
2022
Q2 		– Sell
-139,637
Closed -$338K – 3501
2022
Q1 		$338K Buy
139,637
+2,734
+2% +$6.7K ﹤0.01% 3101
2021
Q4 		$443K Sell
136,903
-11,692
-8% -$48.5K ﹤0.01% 3102
2021
Q3 		$844K Buy
148,595
+4,711
+3% +$28.6K ﹤0.01% 3051
2021
Q2 		$958K Buy
143,884
+3,280
+2% +$21.4K ﹤0.01% 3026
2021
Q1 		$788K Sell
140,604
-8,781
-6% -$84.4K ﹤0.01% 2968
2020
Q4 		$1.18M Buy
149,385
+23,639
+19% +$198K ﹤0.01% 2746
2020
Q3 		$1.07M Buy
125,746
+21,063
+20% +$231K ﹤0.01% 2659
2020
Q2 		$1.09M Sell
104,683
-5,394
-5% -$50.8K ﹤0.01% 2592
2020
Q1 		$1.03M Buy
110,077
+32,218
+41% +$274K ﹤0.01% 2503
2019
Q4 		$624K Sell
77,859
-2,423
-3% -$59.4K ﹤0.01% 2854
2019
Q3 		$1.65M Buy
80,282
+2,557
+3% +$58.6K ﹤0.01% 2490
2019
Q2 		$2.03M Buy
+77,725
New +$2.18M ﹤0.01% 2435

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GP
GSK plc London $602M AUM
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RAM
Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

Nuveen's WVE Position: Q2 2026 in Review

Nuveen reduced its Wave Life Sciences (WVE) stake by 16% in Q2 2026, selling an estimated $719K and leaving 549,282 shares worth $3.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2339.

Nuveen first reported a position in WVE in Q2 2019 and has held it in 25 quarters since. The position peaked at $6.85M in Q4 2024. 239 funds tracked by Wall St. Rank hold WVE as of Q2 2026.

  • Nuveen held 549,282 shares of Wave Life Sciences worth $3.19M as of Q2 2026.
  • Nuveen sold 108,438 Wave Life Sciences shares in Q2 2026, an estimated $719K.
  • Wave Life Sciences made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2339 holding.
  • Nuveen first reported a position in Wave Life Sciences in Q2 2019 and has held it in 25 quarters since.
  • Nuveen's Wave Life Sciences position peaked at $6.85M in Q4 2024.
  • 239 funds tracked by Wall St. Rank held Wave Life Sciences as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.